portal
vein
carri
blood
gastrointestin
tract
liver
carri
microb
well
liver
may
therefor
involv
infect
myriad
number
microbi
organ
infect
commonli
occur
immunocompromis
host
other
affect
immun
compet
hepat
infect
may
primari
natur
secondari
part
system
contagi
diseas
purpos
chapter
provid
brief
overview
variou
infect
liver
pediatr
patient
sever
gramposit
gramneg
bacteri
infect
may
lead
hepat
compromis
includ
infect
staphylococcu
aureu
group
streptococc
speci
common
risk
factor
staphylococcu
aureu
infect
includ
surgic
wound
use
tampon
adolesc
complic
hypotens
shock
may
ensu
hepat
manifest
diseas
includ
elev
serum
transaminas
appear
jaundic
progress
diseas
may
lead
extens
hepat
necrosi
liver
failur
histolog
liver
may
punctuat
microabscess
granuloma
format
treatment
infect
clindamycin
recommend
antibiot
vancomycin
linezolid
may
requir
methicillinresist
infect
studi
cirrhot
patient
spain
extendedspectrum
enterobacteriacea
main
organ
identifi
ed
sepsi
follow
bacteria
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
enterococcu
faecium
septic
shock
vs
p
mortal
rate
vs
p
signifi
cantli
higher
infect
caus
multiresist
strain
thirdgener
cephalosporin
found
clinic
ineffect
treatment
patient
clostridium
perfringen
also
associ
hepat
diseas
clostridi
infect
children
may
occur
newborn
period
set
necrot
enterocol
well
children
receiv
chemotherapi
follow
infect
punctur
wound
develop
ga
gangren
associ
high
mortal
rate
jaundic
may
develop
patient
hepat
diseas
includ
abscess
format
appear
ga
portal
vein
surgic
debrid
affect
tissu
treatment
penicillin
clindamycin
warrant
infect
listeria
neonat
period
describ
sever
infrequ
often
associ
hepat
abscess
format
predispos
factor
includ
prematur
older
children
immunosuppress
diabet
mellitu
cirrhosi
treatment
infect
ampicillin
gentamicin
vaccin
organ
develop
use
immunocompromis
host
develop
world
salmonella
shigella
infect
common
typhoid
fever
particular
lead
system
diseas
frequent
involv
liver
salmonella
typhi
infect
acquir
contamin
foodwat
present
high
fever
abdomin
pain
serum
transaminas
rise
bilirubin
contrast
minim
elev
cholecyst
liver
abscess
format
may
occur
bacteri
endotoxinmedi
hepat
compromis
treat
ciprofl
oxacin
ceftriaxon
fi
rstline
agent
blood
cultur
enzym
immunoassay
bone
marrow
cultur
assist
diagnosi
hepat
may
also
occur
salmonella
paratyphi
b
relat
paratyphoid
fever
treatment
recommend
cephalosporin
fl
uoroquinolon
shigella
infect
lead
dysenteri
acut
diarrheal
ill
acquir
contamin
food
water
infect
common
develop
countri
hepat
manifest
includ
cholestat
hepat
yersinia
enterocolitica
infect
children
present
diarrhea
abdomin
discomfort
often
termin
ileiti
mimic
crohn
diseas
hepat
involv
may
occur
infect
immunocompromis
host
cirrhosi
diabet
may
manifest
multipl
hepat
abscess
format
mortal
instanc
high
treatment
fl
uoroquinolon
indic
pediatr
infect
actinomyc
israelii
occur
immunocompromis
host
includ
cranial
thorac
abdomin
diseas
gramposit
anaerob
bacterium
lead
hepat
infect
abdomin
actinomycosi
case
often
spread
contigu
abdomin
site
diseas
process
usual
indol
nonspecifi
c
elev
infl
ammatori
marker
leukocytosi
liver
may
dot
multipl
abscess
treatment
includ
intraven
penicillin
oral
tetracyclin
surgic
resect
may
requir
larg
abscess
legionnair
diseas
caus
infect
legionella
pneumophila
manifest
pneumonia
hepat
characterist
jaundic
minim
hepat
steatosi
necrosi
may
demonstr
biopsi
treatment
infect
fl
uoroquinolon
azithromycin
may
requir
combin
streptomycin
doxycyclin
use
treatment
infect
organ
lead
q
fever
character
relaps
fever
pneumon
endocard
hepat
characterist
serum
alkalin
phosphatas
elev
disproportion
mild
rise
serum
bilirubin
transaminas
fibrin
ring
granuloma
seen
liver
biopsi
treatment
doxycyclin
bartonella
hensela
infect
cat
scratch
diseas
associ
hepatosplen
necrot
granuloma
peliosi
hepati
bloodfi
lled
cyst
seen
infect
patient
concomit
aid
papular
dermat
pulmonari
neurolog
symptom
may
also
occur
bacillari
angiomatosi
treat
erythromycin
doxycyclin
may
consid
treatment
viscer
diseas
chlamydia
trachomati
infect
describ
perihepat
fitzhughcurti
syndrom
similar
seen
gonococc
diseas
liver
function
test
usual
normal
azithromycin
doxycyclin
use
treatment
infect
rocki
mountain
spot
fever
tickborn
rickettsi
infect
character
develop
maculopapular
rash
fever
hepat
diseas
latter
consist
portal
infl
ammat
vascul
jaundic
increas
liver
enzym
seen
diseas
hemolysi
may
lead
hyperbilirubinemia
biliari
obstruct
contrast
ehrlichia
anoth
tickborn
intracellular
bacteria
infect
associ
liver
injuri
due
prolifer
within
hepatocyt
concomit
immun
respons
focal
necrosi
fi
brin
ring
granuloma
cholestasi
seen
treatment
doxycyclin
indic
leptospirosi
carri
varieti
domest
wild
anim
human
infect
exposur
urin
contamin
soil
water
anicter
leptospirosi
occur
case
usual
biphas
ill
fi
rst
phase
character
fever
conjunctiv
inject
second
phase
associ
myalgia
nausea
vomit
abdomin
pain
time
asept
mening
may
occur
increas
serum
liver
enzym
jaundic
seen
weil
diseas
icter
form
infect
occur
patient
biphas
ill
earlier
phase
mark
jaundic
high
fever
renal
manifest
acut
tubular
necrosi
develop
second
phase
often
lead
renal
failur
high
mortal
hemorrhag
complic
frequent
follow
immun
complex
deposit
lead
capillari
injuri
serolog
test
cultur
help
diagnosi
doxycyclin
usual
use
treatment
lyme
infect
occur
variou
part
usa
exposur
tick
caus
tickborn
spirochet
borrelia
burgdorferi
hepat
diseas
manifest
anorexia
nausea
vomit
weight
loss
right
upper
quadrant
pain
increas
liver
enzym
appear
rash
call
erythema
migran
diagnosi
lyme
diseas
confi
rmed
serolog
typic
clinic
histori
treatment
oral
doxycyclin
azithromycin
develop
countri
tuberculosi
endem
hepat
diseas
often
seen
granuloma
central
caseat
necrosi
found
liver
biopsi
patient
pulmonari
tuberculosi
extrapulmonari
diseas
similar
granuloma
may
found
immunocompromis
individu
vaccin
bacillu
vaccin
diagnosi
base
identifi
cation
acidfast
bacilli
treatment
therapi
jaundic
increas
serum
alkalin
phosphatas
may
also
occur
miliari
diseas
infrequ
seen
children
hepat
involv
may
occur
secondari
syphili
cholestat
hepat
congenit
syphili
describ
frequenc
hepat
rang
addit
nonspecifi
c
symptom
anorexia
weight
loss
characterist
maculopapular
rash
involv
palm
sole
seen
jaundic
well
hepatomegali
right
upper
quadrant
pain
describ
histolog
examin
liver
reveal
hepat
spirochet
demonstr
silver
stain
treatment
infect
penicillin
liver
abscess
format
usual
follow
underli
problem
immunocompromis
diabet
mellitu
surgeri
malign
pyogen
abscess
may
follow
episod
append
perfor
bowel
infl
ammatori
bowel
diseas
pyogen
liver
abscess
may
also
initi
manifest
hepat
malign
abscess
due
infect
escherichia
coli
klebsiella
proteu
pseudomona
streptococcu
anaerob
infect
bacteroid
may
also
occur
addit
clostridium
actinomyc
yersinia
haemophilu
infl
uenza
listeria
staphylococcu
may
lead
liver
abscess
format
dissemin
fungal
infect
may
lead
microor
macroabscess
format
immunocompromis
host
patient
typic
present
abdomin
discomfort
sever
right
upper
abdomin
pain
high
fever
physic
examin
identifi
es
tender
hepatomegali
ultrasound
ct
scan
initi
imag
modal
choic
allow
small
abscess
cm
diamet
identifi
ed
ct
scan
identifi
es
local
abscess
defi
ne
whether
ga
abscess
allow
aspir
cultur
insert
drain
necessari
treatment
pyogen
liver
abscess
drainag
pu
initi
appropri
antibiot
treatment
indwel
cathet
may
place
abscess
caviti
abscess
larger
cm
size
intermitt
needl
aspir
may
attempt
multipl
abscess
larg
one
need
aspir
small
abscess
treat
antibiot
therapi
alon
initi
antibiot
treatment
cultur
result
avail
broaden
cover
number
organ
usual
amoxicillin
aminoglycosid
well
thirdgener
cephalosporin
anaerob
coverag
may
also
requir
metronidazol
treatment
intraven
least
week
oral
week
streptococc
infect
highdos
oral
antibiot
may
requir
month
mortal
rate
despit
treatment
high
complic
delay
diagnos
includ
shock
pleural
effus
sepsi
multiorgan
dysfunct
malaria
infect
protozoan
speci
plasmodia
estim
peopl
infect
global
parasit
everi
year
major
speci
differ
life
cycl
well
presenc
absenc
hepat
phase
plasmodium
falciparum
plasmodium
malaria
associ
hepat
cycl
plasmodium
vivax
oval
persist
exoerythrocyt
phase
liver
extent
hepat
injuri
relat
speci
sever
infect
activ
hemolysi
lead
increas
unconjug
fraction
bilirubin
howev
hepatocellular
dysfunct
set
conjug
fraction
bilirubin
begin
rise
well
liver
failur
lead
liver
synthet
function
impair
decreas
serum
albumin
prolong
prothrombin
time
hyperglycemia
lactic
acidosi
late
complic
high
mortal
diseas
congenit
malaria
although
rare
may
also
lead
sever
even
fulmin
liver
diseas
newborn
infant
diagnosi
malaria
requir
histori
physic
examin
identifi
cation
parasit
blood
smear
rapid
antigen
detect
assay
avail
treatment
depend
speci
plasmodium
chloroquin
may
effect
mani
part
world
chloroquin
resist
increasingli
seen
area
treatment
requir
mefl
oquin
quinin
pyrimethaminesulfadoxin
proguanil
also
use
treatment
babesia
transmit
deer
tick
ixod
scapulari
infect
manifest
fever
anemia
hepatosplenomegali
infect
individu
typic
anemia
hemoglobinuria
hemophagocytosi
bone
marrow
examin
treatment
azithromycin
atovaquon
clindamycin
quinin
complic
case
exchang
transfus
may
requir
leishmaniasi
caus
leishmania
donovani
transmit
sand
fl
endem
mediterranean
central
asian
south
asian
region
well
africa
south
america
new
guinea
papular
ulcer
lesion
occur
bite
site
follow
period
time
rang
month
year
fever
weight
loss
diarrhea
massiv
hepatosplenomegali
hepatocyt
necrosi
follow
cirrhosi
complic
chronic
liver
diseas
diagnosi
base
characterist
clinic
featur
histori
identif
parasit
wright
giemsa
leishman
jenner
stain
buffycoat
prepar
peripher
blood
aspir
marrow
spleen
liver
lymph
node
skin
lesion
spread
slide
make
thin
smear
pancytopenia
increas
predisposit
secondari
bacteri
infect
pneumococc
infect
tuberculosi
may
occur
cutan
pigment
may
also
seen
treatment
infect
pentaval
antimoni
altern
parenter
agent
includ
liposom
amphotericin
b
paromomycin
miltefosin
phosphocholin
analogu
also
use
treatment
toxoplasma
gondii
infect
may
acquir
congenit
ingest
oocyt
contamin
meat
soil
water
hepat
involv
may
occur
sever
dissemin
infect
patient
typic
present
fever
headach
lymphadenopathi
hepatosplenomegali
myocard
enceph
may
also
occur
diagnosi
made
identifi
cation
specifi
c
antibodi
enzym
immun
assay
treatment
combin
pyrimethamin
sulfadiazin
folin
acid
amoeb
infect
liver
occur
commonli
develop
world
patient
present
abdomin
pain
enlarg
liver
may
histori
preced
diarrhea
pulmonari
featur
well
pericardi
involv
periton
may
occur
rare
diagnosi
amoeb
liver
abscess
base
good
histori
clinic
exam
imag
serolog
analysi
howev
import
note
serolog
test
may
need
interpret
caution
antibodi
may
remain
elev
sever
year
treatment
aspir
may
attempt
diagnosi
unclear
characterist
reddishbrown
anchovi
past
aspir
treatment
includ
antibiot
metronidazol
month
necessari
intraven
day
tinidazol
chloroquin
may
use
oral
lumin
amebacid
diloxanid
furoat
iodoquinol
use
follow
cours
metronidazol
addit
day
although
liver
infect
helminth
occur
infrequ
develop
countri
contrast
hepat
diseas
nematod
seen
often
develop
world
toxocara
cani
cati
infect
dog
cat
respect
may
ultim
lead
human
diseas
viscer
larva
migran
seen
commonli
children
histori
pica
ingest
present
fever
hepatomegali
urticaria
increas
eosinophil
count
infect
lead
cholestat
hepat
liver
abscess
format
pulmonari
diseas
asthma
pneumonia
may
seen
neurolog
involv
seizur
encephalopathi
may
also
occur
migrat
eye
associ
visual
loss
liver
biopsi
may
necessari
enzym
immunoassay
confi
rm
diagnosi
treatment
infect
mebendazol
albendazol
ascari
lumbricoid
affect
least
one
million
peopl
develop
world
infect
ingest
contamin
fruit
veget
may
respiratori
symptom
cough
wheez
occasion
hepatomegali
infect
biliari
tree
lead
calculu
format
obstruct
jaundic
cholang
liver
abscess
may
seen
treatment
mebendazol
albendazol
pyrantel
pamoat
endoscop
surgic
intervent
may
requir
intestin
biliari
obstruct
strongyloid
stercorali
preval
mostli
tropic
larva
penetr
skin
carri
lung
swallow
reach
intestin
matur
occur
symptom
acut
infect
includ
pruritu
abdomin
discomfort
diarrhea
hepat
infect
lead
jaundic
cholestasi
periport
infl
ammat
eosinophil
granuloma
seen
biopsi
diagnosi
achiev
serolog
test
identifi
cation
larva
stool
intestin
biopsi
specimen
treatment
acut
infect
ivermectin
albendazol
trichinella
spirali
acquir
ingest
contamin
raw
pork
larva
may
found
liver
gallbladd
clinic
manifest
includ
diarrhea
fever
mark
eosinophilia
obstruct
jaundic
diagnosi
suggest
characterist
histori
serolog
analysi
muscl
biopsi
may
help
confi
rm
diagnosi
treatment
antihelminth
albendazol
mebendazol
schistosoma
infect
found
variou
part
world
commonli
area
africa
middl
east
schistosoma
intercalatum
particular
caus
liver
diseas
cercaria
penetr
skin
proceed
lung
liver
adult
fl
uke
may
also
migrat
mesenter
vasculatur
egg
induc
granulomat
respons
clinic
featur
schistosomiasi
includ
headach
fever
cough
tender
liver
diarrhea
chronic
liver
diseas
describ
portal
hypertens
gastroesophag
varic
ascit
splenomegali
chronic
infect
may
associ
increas
suscept
salmonella
infect
frequent
coexist
hepat
b
c
viral
infect
endem
area
lead
progress
liver
diseas
increas
predisposit
hepatocellular
carcinoma
stool
test
serolog
analysi
aid
diagnosi
liver
biopsi
demonstr
periport
fi
brosi
infect
treat
praziquantel
fasciola
hepatica
caus
liver
fl
uke
lead
acut
chronic
obstruct
hepat
diseas
clinic
featur
mark
fever
right
upper
quadrant
pain
eosinophilia
enlarg
liver
appreci
exam
chronic
obstruct
phase
character
intrahepat
extrahepat
bile
duct
infl
ammat
lead
cholang
stone
format
obstruct
diagnosi
antibodi
detect
identifi
cation
egg
stool
duoden
aspir
bile
treatment
triclabendazol
clonorchi
sinensi
infect
acquir
ingest
contamin
seafood
clinic
featur
fever
abdomin
pain
diarrhea
physic
exam
tender
hepatomegali
appreci
biliari
obstruct
stone
format
may
also
occur
may
recurr
pyogen
cholang
cholangiocarcinoma
may
aris
diagnosi
detect
characterist
egg
stool
identif
fl
uke
bile
duct
gallbladd
treatment
praziquantel
echinococcu
granulosu
also
found
mani
area
world
infect
occur
ingest
contamin
food
liver
commonli
involv
follow
lung
kidney
spleen
brain
cyst
liver
call
hydatid
cyst
cyst
characterist
layer
imag
patient
asymptomat
howev
cyst
increas
size
may
lead
abdomin
pain
tender
enlarg
liver
cyst
may
ruptur
lung
may
induc
lifethreaten
anaphylact
reaction
may
also
ruptur
biliari
tree
may
induc
cholang
obstruct
rare
complic
includ
pancreat
portal
hypertens
buddchiari
syndrom
infect
bile
duct
may
lead
liver
abscess
format
well
diagnosi
requir
identifi
cation
ringlik
hepat
calcifi
cation
plain
xray
imag
ultrasound
comput
tomographi
ct
scan
confi
rmation
diagnosi
percutan
aspir
cyst
may
associ
anaphylact
reaction
therefor
tradit
discourag
howev
aspir
may
attempt
care
control
circumst
treatment
includ
surgic
cystectomi
marsupi
advanc
case
hepat
resect
calcifi
ed
cyst
need
remov
percutan
drainag
may
attempt
complic
cyst
administr
albendazol
week
recommend
candida
albican
infect
frequent
seen
sever
immunocompromis
individu
may
lead
hepat
abscess
format
multiorgan
diseas
dissemin
seed
portal
vein
lead
format
small
abscess
liver
ct
scan
abdomen
use
test
identifi
tini
abscess
clinic
featur
includ
fever
abdomin
discomfort
tender
hepatomegali
serum
aminotransferas
bilirubin
alkalin
phosphatas
level
elev
high
mortal
rate
treatment
infect
intraven
amphotericin
b
altern
treatment
includ
fl
uconazol
liposom
amphotericin
caspofungin
micafungin
anidulafungin
histoplasma
capsulatum
infect
acquir
via
respiratori
tract
patient
immunodefici
may
manifest
fever
hepatosplenomegali
lymphadenopathi
liver
biopsi
done
identifi
yeast
area
caseat
necrosi
granuloma
treatment
amphotericin
b
fl
uconazol
hepat
viru
hav
enteroviru
belong
picornavirida
famili
icosahedr
shape
lack
envelop
virion
measur
nm
diamet
one
known
serotyp
hav
genom
consist
posit
sens
rna
kb
long
singl
strand
linear
hav
rna
long
open
read
frame
consist
nucleotid
numer
strain
viru
exist
consider
sequenc
variabl
human
hav
group
genotyp
simian
strain
belong
genotyp
antigen
structur
human
hav
highli
conserv
differ
genom
may
play
role
develop
fulmin
hepat
failur
incid
hepat
viru
infect
declin
usa
sinc
sinc
infect
asymptomat
true
number
infect
may
underreport
infect
occur
among
children
age
year
usa
epidemiolog
infect
unknown
patient
attribut
intern
travel
contact
patient
hepat
men
sex
men
contamin
food
water
children
employe
daycar
center
contact
daycar
child
employe
inject
drug
use
develop
world
poor
hygien
condit
children
infect
earli
life
shown
almost
children
countri
immun
year
age
also
shown
symptomat
infect
common
older
children
primari
transmiss
fecalor
persontoperson
contact
ingest
contamin
foodwat
parenter
transmiss
describ
rare
risk
perinat
transmiss
small
transmiss
infect
neonat
period
also
rare
howev
describ
neonat
intens
care
unit
attribut
transfus
contamin
blood
plasma
horizont
spread
infect
person
viru
infect
liver
pathogenesi
injuri
yet
well
defi
ned
immunolog
mediat
injuri
hepatocyt
seem
like
mechan
hav
hepat
acut
infect
develop
chronic
diseas
may
prolong
relaps
cours
signifi
cant
cholestasi
relaps
cours
occur
week
period
observ
approxim
patient
acut
hepat
rare
acut
hepat
failur
may
occur
incub
period
short
week
previous
healthi
children
morbid
mortal
low
higher
older
children
adult
younger
children
usual
asymptomat
jaundic
may
develop
patient
icteru
seen
often
children
older
year
age
hav
infect
associ
higher
mortal
pregnant
woman
clinic
featur
anorexia
nausea
vomit
abdomin
pain
myalgia
diarrhea
may
also
occur
dark
urin
preced
symptom
approxim
infect
peopl
symptom
abdomin
discomfort
last
day
sever
week
usual
declin
jaundic
becom
manifest
complet
clinic
recoveri
achiev
patient
within
month
overal
prognosi
excel
although
infect
may
associ
fatal
complic
acut
hepat
failur
seen
rare
children
case
fatal
rate
individu
older
year
compar
overal
rate
person
age
fulmin
failur
usual
becom
obviou
fi
rst
week
ill
major
patient
increas
morbid
high
risk
liver
failur
elderli
chronic
liver
diseas
hiv
unlik
hepat
b
viru
infect
arthralgia
rash
vascul
glomerular
nephriti
uncommon
acut
hepat
extrahepat
manifest
includ
myocard
renal
failur
optic
neuriti
transvers
myeliti
polyneur
cholecyst
aplast
anemia
red
cell
aplasia
may
occur
autoimmun
hepat
also
describ
follow
infect
viru
diagnosi
infect
detect
specifi
c
antibodi
serum
elev
antihav
igm
indic
acut
infect
detect
serum
onset
symptom
may
remain
posit
approxim
month
patient
may
low
level
igm
antibodi
almost
year
initi
infect
igg
antibodi
remain
present
life
indic
previou
infect
vaccin
test
rna
limit
research
rna
detect
bodi
fl
uid
serum
stool
liver
tissu
vaccin
infect
licens
use
month
age
univers
childhood
vaccin
adopt
hope
elimin
transmiss
usa
led
declin
incid
rate
among
children
highrisk
popul
viru
usa
greatest
risk
healthi
individu
travel
endem
area
men
sex
men
patient
posit
hiv
patient
underli
chronic
liver
diseas
drug
use
specifi
c
medic
treat
acut
hepat
administr
serum
immunoglobulin
mainstay
prevent
infect
avail
vaccin
render
use
immunoglobulin
preexposur
prophylaxi
rel
unnecessari
vaccin
also
use
postexposur
prophylaxi
sinc
earli
advisori
committe
immun
practic
suggest
recent
expos
viru
vaccin
previous
given
singl
dose
vaccin
immunoglobulin
soon
possibl
ideal
within
week
exposur
sinc
immunoglobulin
prepar
deriv
blood
product
concern
use
postexposur
prophylaxi
immunoglobulin
administ
time
initi
activ
immun
vaccin
patient
concomit
chronic
liver
diseas
particularli
need
protect
hav
vaccin
recommend
individu
hepat
e
hev
viru
small
rna
viru
nm
diamet
nonenvelop
icosahedr
particl
belong
famili
hepevirida
contain
three
open
read
frame
orf
open
read
frame
orf
includ
nonstructur
protein
encod
viru
capsid
protein
encod
protein
unknown
function
detail
replic
liver
cell
releas
infect
cell
remain
unknown
four
differ
genotyp
genotyp
found
asia
genotyp
mexico
western
africa
usa
genotyp
infect
genotyp
also
report
sever
european
countri
genotyp
china
taiwan
japan
vietnam
genotyp
belong
singl
serotyp
sever
epidem
viru
indian
subcontin
well
central
asia
middl
east
africa
overal
attack
rate
rang
higher
adult
children
children
attack
rate
high
mortal
among
pregnant
women
endem
area
hepat
e
account
case
sporad
acut
hepat
countri
nonendem
infect
relat
travel
endem
area
patient
asymptomat
jaundic
although
patient
icter
viru
transmit
ingest
contamin
food
water
outbreak
frequent
follow
monsoon
season
secondari
attack
rate
among
household
contact
rang
thought
contamin
water
sourc
subclin
infect
anim
reservoir
prolong
fecal
shed
lead
persist
viru
commun
countri
india
antibodi
hepat
viru
almost
univers
detect
earli
childhood
adolesc
howev
antibodi
develop
hepat
e
contrast
remain
uncommon
infect
incub
period
week
viru
detect
stool
approxim
week
onset
ill
week
fecal
shed
continu
week
onset
ill
histopatholog
featur
infect
similar
form
acut
hepat
massiv
necrosi
seen
rare
chronic
hev
viremia
genotyp
viru
report
kidney
liver
transplant
patient
europ
suggest
infect
may
potenti
lead
chronic
liver
diseas
symptom
hepat
includ
fever
abdomin
pain
anorexia
nausea
vomit
period
cholestasi
stool
clay
color
urin
dark
pruritu
transient
macular
rash
may
seen
physic
exam
demonstr
jaundic
enlarg
tender
liver
serum
transaminas
elev
conjug
hyperbilirubinemia
ultrasound
demonstr
mildli
enlarg
liver
viral
infect
hev
selflimit
case
fatal
rate
describ
pregnant
women
particularli
second
third
trimest
affect
frequent
wors
outcom
mortal
patient
epidem
india
clinic
hepat
develop
pregnant
women
fulmin
hepat
failur
seen
approxim
infect
pregnant
women
increas
frequenc
complic
diagnosi
requir
detect
viru
stool
serum
pcr
done
look
hev
rna
enzym
immun
assay
detect
igm
igg
antibodi
develop
presenc
serum
igm
antibodi
indic
acut
infect
presenc
igg
indic
past
diseas
treatment
support
specifi
c
medic
prevent
hepat
e
endem
area
compris
improv
hygien
antibodi
fulli
protect
seen
occurr
larg
epidem
among
adult
live
endem
area
candid
vaccin
develop
current
studi
nepal
igg
antibodi
observ
third
vaccin
dose
although
volunt
high
antibodi
titer
end
studi
vaccin
may
potenti
use
travel
endem
area
hepat
b
viru
hbv
infect
worldwid
health
problem
caus
acut
liver
failur
acut
hepat
chronic
hepat
cirrhosi
liver
cancer
preval
asia
africa
southern
europ
latin
america
hepat
b
surfac
antigen
hbsag
posit
rate
gener
popul
rang
approxim
two
billion
peopl
world
infect
hbv
million
chronic
hbsag
carrier
endem
area
hbv
infect
occur
mainli
infanc
earli
childhood
mothertoinf
transmiss
account
approxim
half
chronic
hbv
infect
contrast
infect
adult
hbv
infect
earli
childhood
result
much
higher
rate
persist
infect
longterm
seriou
sequela
liver
cirrhosi
hepatocellular
carcinoma
hcc
hbv
carrier
lifetim
risk
develop
hcc
incid
cirrhosi
year
hepat
b
viru
envelop
dna
viru
member
hepadnavirida
famili
sever
import
structur
includ
surfac
antigen
core
antigen
e
antigen
variou
test
develop
differ
structur
help
make
diagnosi
hepat
b
ten
genotyp
j
sever
subtyp
describ
genotyp
preval
north
america
europ
viru
transmit
predominantli
parenter
rout
sexual
contact
perinat
exposur
acut
ill
may
vari
manifest
major
develop
antibodi
infect
immun
go
develop
chronic
diseas
approxim
fulmin
failur
exposur
risk
develop
chronic
infect
inde
higher
newborn
infant
children
year
age
adolesc
adult
reduc
mothertochild
transmiss
world
health
organ
recommend
administr
vaccin
hepat
b
immunoglobulin
hbig
newborn
hbsagposit
mother
within
h
birth
protect
rate
hbsag
hbv
dna
detect
breast
milk
chronic
carrier
increas
risk
transmiss
breastf
infant
shown
breastfeed
current
recommend
proper
infant
immun
neonat
infect
rare
show
sign
diseas
may
transient
mild
acut
hepat
chronic
persist
hepat
specifi
c
therapi
acut
infect
neonat
three
phase
chronic
hepat
b
identifi
ed
immunetoler
phase
immuneact
phase
inact
phase
children
chronic
hbv
infect
immun
toler
high
viral
replic
posit
hepat
b
envelop
antigen
hbeag
high
hbv
deoxyribonucl
acid
dna
level
normal
level
aminotransferas
pattern
mainli
seen
children
infect
birth
immunetoler
phase
may
last
long
adulthood
howev
children
go
immuneact
phase
phase
mark
activ
infl
ammat
elev
aminotransferas
may
develop
fi
brosi
time
individu
sudden
elev
aminotransferas
undergo
spontan
hbeag
antihb
seroconvers
hbeag
clearanc
aminotransferas
level
gradual
return
normal
limit
antihb
develop
spontan
major
individu
demonstr
clearanc
enter
inact
carrier
state
normal
aminotransferas
reduct
hbv
dna
level
improv
hepat
infl
ammat
fraction
patient
retain
hepat
infl
ammat
elev
aminotransferas
hbv
dna
remain
immuneact
state
greater
risk
develop
cirrhosi
hcc
risk
factor
associ
progress
hepat
infl
ammat
subsequ
complic
includ
hbv
genotyp
persist
viremia
specifi
c
mutat
hbv
genom
optim
goal
antivir
therapi
chronic
hbv
infect
erad
hbv
prevent
relat
liver
complic
shorten
durat
liver
infl
ammat
howev
due
limit
effect
avail
therapi
viral
erad
goal
current
antivir
therapi
hepat
b
reduc
viral
replic
minim
liver
injuri
reduc
infect
tabl
guidelin
treatment
repres
fig
interferonalpha
ifnalpha
deliv
subcutan
inject
fi
rst
approv
therapi
hbv
predictor
ifn
respons
includ
activ
hepat
low
hbv
dna
level
pg
ml
high
serum
alanin
aminotransferas
alt
uln
short
durat
diseas
nonasian
ethnic
origin
horizont
transmiss
basi
european
experi
consensu
recommend
use
ifnalpha
hbv
infect
children
develop
main
goal
therapi
accord
recommend
acceler
hbeag
clearanc
children
hbeag
hbv
dna
posit
lowintermedi
hbv
dna
level
abnorm
aminotransferas
enzym
age
year
older
ifn
therapi
less
like
benefi
children
perinat
acquir
infect
normal
minim
elev
aminotransferas
recommend
treatment
regimen
ifnalpha
fi
ten
million
unit
per
squar
meter
thrice
weekli
subcutan
inject
month
respons
rate
variabl
depend
rout
acquisit
ethnic
origin
diseas
activ
treatment
regim
adult
data
suggest
hbeagneg
chronic
diseas
treat
month
wherea
other
demonstr
longer
durat
treatment
month
increas
sustain
respons
rate
pretreat
corticosteroid
prime
withdraw
commenc
ifnalpha
may
exacerb
host
immun
respons
facilit
seroconvers
benefi
howev
remain
unproven
associ
risk
precipit
fulmin
liver
failur
thought
simpli
acceler
seroconvers
mani
patient
respond
treatment
may
still
seroconvert
antihb
later
life
seri
children
follow
year
treat
patient
elev
baselin
alt
level
hbsag
clearanc
observ
children
treat
ifn
respond
compar
control
contraind
children
decompens
cirrhosi
cytopenia
autoimmun
diseas
side
effect
treatment
includ
fever
fl
ulik
symptom
behavior
disord
gastrointestin
disord
u
shah
neutropenia
furthermor
shown
temporarili
affect
growth
pegyl
interferonalpha
pegifn
yet
approv
treatment
chronic
hepat
b
children
lamivudin
oral
administ
pyrimidin
nucleosid
analogu
prevent
replic
hbv
infect
hepatocyt
incorpor
viral
dna
lead
chain
termin
competit
inhibit
viral
revers
transcriptas
viral
respons
achiev
children
receiv
lamivudin
treatment
compar
control
group
respons
increas
children
alt
level
least
twice
uln
end
year
treatment
respons
rate
children
receiv
lamivudin
absenc
resist
mutat
resist
rate
increas
time
year
treatment
year
year
recommend
treatment
dose
mgkg
day
maximum
mgday
administ
oral
daili
longer
treatment
lead
higher
resist
rate
therefor
recommend
lamivudin
discontinu
month
lack
complet
viral
suppress
ymdd
mutant
emerg
altern
therapi
consid
sever
protract
transamin
combin
therapi
lamivudineifna
either
concurr
sequenti
prove
effect
singl
drug
alon
adult
patient
elev
alt
level
three
studi
children
investig
therapi
children
elev
alt
level
although
differ
found
differ
combin
strategi
children
reach
seroconvers
antihb
antihb
larg
clinic
trial
conduct
far
advantag
combin
therapi
monotherapi
children
still
unclear
adefovir
dipivoxil
purin
analogu
approv
treat
children
chronic
hepat
b
age
year
older
patient
mutat
rare
children
adefovirresist
mutat
report
hbeagposit
adult
treatment
proxim
renal
tubular
toxic
side
effect
adefovir
rare
report
adult
children
patient
hbeagposit
chronic
hbv
infect
continu
treatment
least
month
seroconvers
discontinu
treatment
incomplet
viral
suppress
week
entecavir
carbocycl
analogu
prove
effect
adult
patient
resist
rare
even
year
treatment
approv
fda
treatment
adolesc
age
year
older
recommend
dose
mg
daili
patient
mgday
lamivudineresist
patient
phase
iii
clinic
trial
children
young
year
old
underway
telbivudin
lnucleosid
analogu
potent
antivir
activ
safeti
profi
le
similar
lamivudin
although
myopathi
peripher
neuropathi
report
adult
resist
rate
lower
lamivudin
higher
adefovir
therefor
telbivudin
use
combin
antivir
drug
phase
clinic
trial
ongo
children
year
age
tenofovir
disoproxil
fumar
nucleosid
analogu
origin
licens
treatment
hiv
infect
dose
tenofovir
adult
higher
adefovir
mgday
greater
antivir
activ
adefovir
clinic
trial
undetect
hbv
dna
patient
vs
adefovirreceiv
subject
week
treatment
genotyp
resist
tenofovir
yet
confi
rmed
phase
iii
trial
ongo
patient
tabl
hepat
delta
viru
hdv
close
associ
hepat
b
viru
hbv
infect
simultan
presenc
hbv
requir
complet
virion
assembl
secret
hbv
replic
suppress
hdvinfect
individu
hdv
genom
small
rna
molecul
express
hdv
antigen
coinfect
hbv
hdv
result
acut
hepat
usual
transient
selflimit
howev
high
incid
liver
failur
report
among
drug
user
hdv
superinfect
chronic
hbsag
carrier
may
present
sever
acut
hepat
previous
unrecogn
hbv
carrier
exacerb
preexist
chronic
hepat
b
progress
chronic
hdv
infect
occur
hbv
replic
usual
suppress
western
world
predomin
hdv
genotyp
genotyp
acut
hepat
increas
risk
fulmin
diseas
chronic
hdv
infect
exacerb
preexist
liver
diseas
patient
hepat
b
rapidli
progress
cirrhosi
far
east
predomin
genotyp
genotyp
less
frequent
fulmin
hepat
acut
hdv
infect
rapidli
progress
liver
diseas
chronic
hdv
sever
outbreak
acut
hepat
high
incid
liver
failur
report
south
america
genotyp
drug
approv
present
treatment
chronic
hepat
largest
multicent
trial
italian
patient
chronic
hepat
randomli
assign
receiv
dose
mum
three
time
weekli
month
follow
mum
three
time
weekli
addit
month
placebo
follow
anoth
month
twentyfi
percent
treat
patient
normal
serum
transaminas
versu
none
control
end
studi
one
respond
biochem
relaps
discontinu
treatment
littl
data
pegyl
interferon
treatment
chronic
hepat
largest
publish
studi
includ
patient
treat
pegyl
ifn
mukg
week
alon
combin
ribavirin
week
patient
maintain
pegyl
ifn
addit
week
follow
week
end
followup
hdv
rna
detect
respons
rate
similar
monotherapi
combin
therapi
group
suggest
ribavirin
effect
viral
clearanc
higher
virolog
respons
rate
found
anoth
studi
month
pegyl
ifn
combin
therapi
nucleosid
nucleotid
analogu
encourag
current
standard
recommend
treatment
pediatr
hdv
infect
mainstay
prevent
hdv
infect
vaccin
helper
viru
hbv
hcv
rna
viru
affect
million
individu
worldwid
usa
antibodi
hcv
present
approxim
children
age
age
overal
approxim
new
hcv
infect
occur
usa
year
although
specifi
c
incid
children
unknown
chronic
hcv
infect
estim
affect
children
usa
perinat
transmiss
common
sourc
infect
children
adolesc
may
expos
intraven
intranas
drug
use
use
share
tattoo
needl
incid
hcv
vertic
transmiss
approxim
hcv
rna
posit
mother
highest
risk
mother
high
hcv
viral
load
risk
also
increas
fourfold
mother
concomit
hiv
coinfect
six
major
genotyp
hcv
defi
ned
greater
subtyp
genotyp
common
usa
europ
genotyp
less
common
area
genotyp
rare
genotyp
common
india
far
east
australia
genotyp
common
africa
middl
east
genotyp
common
south
africa
genotyp
common
hong
kong
vietnam
australia
common
subtyp
viral
genotyp
affect
respons
interferon
therapi
sustain
virolog
respons
pegyl
interferon
plu
ribavirin
rang
percent
genotyp
includ
high
genotyp
infect
acquir
infanc
like
resolv
spontan
clearanc
rate
rang
describ
followup
perinat
acquir
hcv
children
approxim
clear
infect
chronic
diseas
diseas
progress
slowli
therefor
advanc
liver
diseas
uncommon
children
howev
progress
advanc
fi
brosi
cirrhosi
childhood
report
patient
suspect
chronic
hepat
c
viru
hcv
infect
risk
factor
hcv
test
hcv
antibodi
hcv
rna
test
perform
posit
antibodi
test
confi
rm
infect
unexplain
liver
diseas
whose
antihcv
test
neg
immunocompromis
hcv
rna
quantit
viral
load
obtain
patient
consid
treatment
quantit
qualit
test
use
treatment
assess
respons
hcv
genotyp
determin
infect
person
prior
treatment
determin
durat
therapi
dose
ribavirin
likelihood
respons
tabl
naspghan
guidelin
recommend
test
antihcv
antibodi
infant
month
age
confi
rmation
pcr
posit
parent
desir
hcv
rna
may
test
fi
rst
year
life
howev
infant
must
older
month
age
test
chronic
infect
hcv
associ
hepatocellular
carcinoma
hcc
cirrhosi
result
hcc
rare
among
children
infect
hcv
appear
common
children
develop
hcv
treatment
childhood
leukemia
children
hepat
c
persist
elev
serum
aminotransferas
fi
brosi
liver
histolog
consid
treatment
present
avail
treatment
ribavirin
aasld
naspghan
recommend
fdaapprov
combin
ribavirin
fi
rstline
treatment
children
age
year
may
two
proteas
inhibitor
boceprevir
telaprevir
licens
usa
use
combin
pegyl
interferon
ribavirin
adult
chronic
hcv
genotyp
therapi
associ
signifi
cantli
higher
rate
sustain
virolog
respons
compar
combin
pegyl
interferon
ribavirin
pediatr
trial
combin
therapi
boceprevir
underway
trial
telaprevir
plan
practic
recommend
children
chronic
hcv
similar
adult
howev
limit
data
pediatr
age
group
treatment
decis
may
vari
child
age
individu
diseas
characterist
combin
treatment
pegyl
interferon
plu
ribavirin
consid
children
chronic
hcv
infect
older
year
appear
progress
diseas
advanc
histolog
featur
children
cours
action
depend
hcv
genotyp
newer
potenti
treatment
includ
direct
act
antivir
possibl
option
may
minim
use
inject
therapi
tabl
hepat
g
viru
hgv
discov
incident
name
surgeon
develop
jaundic
serum
led
identifi
cation
gbva
gbvb
gbvc
subsequ
studi
identifi
ed
associ
infect
gbv
acut
hepat
therefor
term
hepat
g
viru
question
positivestrand
rna
viru
belong
flavivirida
famili
gb
vc
share
homolog
hcv
viru
found
worldwid
fi
differ
genotyp
develop
antibodi
correl
loss
viremia
suggest
past
exposur
clearanc
infect
healthi
blood
donor
posit
antibodi
much
lower
rate
activ
viremia
rate
natur
clearanc
viru
higher
hepat
c
although
gbvc
detect
mani
patient
chronic
hepat
unclear
etiolog
appear
caus
liver
diseas
durat
infect
depend
immun
statu
age
patient
associ
found
malign
aplast
anemia
antibodi
check
document
past
infect
pcr
analysi
may
done
viru
fi
rst
identifi
ed
also
known
transfus
transmit
viru
nonenvelop
singlestrand
dna
viru
believ
hepatotrop
found
worldwid
common
found
healthi
blood
donor
transmit
parenter
rout
although
associ
hepat
fi
rst
patient
identifi
ed
studi
support
relationship
liver
diseas
viru
sever
similar
virus
sanban
yonban
sen
virus
also
identifi
ed
clinic
signifi
canc
remain
controversi
infect
viru
myriad
clinic
present
infant
young
children
asymptomat
nonspecifi
c
complaint
adolesc
may
fever
lymphadenopathi
pharyng
subclin
liver
diseas
may
occur
overt
diseas
rang
mild
transamin
hepat
necrosi
fulmin
failur
serum
lactic
dehydrogenas
may
elev
three
time
uln
alkalin
phosphatas
elev
hyperbilirubinemia
also
seen
patient
laboratori
abnorm
slow
resolv
cholestat
jaundic
pruritu
may
occur
women
ebv
hepat
take
oral
contracept
pill
fatal
fulmin
hepat
describ
immunocompromis
patient
well
immunocompet
fever
hepatosplenomegali
liver
failur
bone
marrow
suppress
hyperferritinemia
may
develop
hemophagocyt
syndrom
associ
ebv
infect
diagnosi
ebv
hepat
base
clinic
featur
well
test
support
diagnosi
predomin
lymphocytosi
monocytosi
thrombocytopenia
monospot
test
may
posit
igm
antibodi
seen
earli
diseas
igg
antibodi
indic
possibl
past
infect
import
note
monospot
test
howev
may
fals
neg
abdomin
ultrasound
frequent
demonstr
hepatosplenomegali
lymphadenopathi
gallbladd
thicken
liver
biopsi
rare
necessari
diagnosi
specifi
c
therapi
ebv
hepat
acyclovir
inhibit
replic
ebv
effect
clinic
symptom
outcom
improv
acut
chronic
ebv
hepat
report
ganciclovir
treatment
yet
well
studi
liver
transplant
perform
fulmin
hepat
caus
ebv
cytomegaloviru
cmv
member
herp
famili
persist
life
nonrepl
state
clinic
diseas
may
occur
primari
infect
reactiv
immunocompromis
patient
immunocompet
primari
infect
usual
subclin
may
mimic
infect
ebv
hepat
diseas
character
increas
liver
enzym
alkalin
phosphatas
without
organomegali
clinic
cours
usual
mild
howev
occasion
may
hepat
necrosi
congenit
infect
cmv
jaundic
hepatosplenomegali
thrombocytopen
purpura
sever
neurolog
impair
describ
portal
vein
thrombosi
may
occur
dissemin
diseas
occur
immunocompromis
host
may
manifest
hepat
pancreat
rare
gangren
cholecyst
cmv
describ
aidsassoci
cholangiopathi
primari
scleros
cholang
cmv
hepat
may
diffi
cult
distinguish
graft
reject
liver
transplant
patient
differenti
crucial
appropri
manag
diagnosi
requir
serolog
analysi
liver
biopsi
igm
antibodi
demonstr
acut
infect
pcr
use
confi
rmation
particularli
immunocompromis
patient
multinucl
giant
cell
mononuclear
portal
infi
ltrate
seen
liver
biopsi
characterist
intranuclear
inclus
call
owl
eye
inclus
ganciclovir
use
treatment
altern
agent
includ
foscarnet
cidofovir
hsv
hepat
seen
immunocompromis
individu
neonat
infect
may
rapidli
progress
life
threaten
neonat
may
expos
infect
matern
secret
time
deliveri
pregnant
women
hepat
may
fulmin
therefor
high
matern
perinat
mortal
approxim
prompt
diagnosi
treatment
extrem
import
liver
biopsi
requir
diagnosi
extens
hemorrhag
necrosi
may
seen
biopsi
intranuclear
inclus
cowdri
bodi
hepatocyt
may
ground
glass
appear
treatment
acyclovir
liver
transplant
may
indic
sever
diseas
children
infect
viru
may
demonstr
hepat
increas
liver
enzym
albeit
rare
dissemin
infect
lead
viscer
involv
describ
onset
cutan
featur
patient
receiv
solid
organ
transplant
form
immunodefi
cienci
viscer
involv
suspect
highdos
intraven
acyclovir
requir
transplant
patient
morbid
mortal
due
infect
remain
persist
problem
infect
includ
bacteri
viral
fungal
pathogen
import
note
solid
organ
transplant
recipi
sign
symptom
infect
often
blunt
set
immun
suppress
addit
antibiot
antimicrobi
use
may
interact
immunosuppress
medic
import
risk
factor
presenc
latent
infect
either
transplant
recipi
donor
potenti
transplant
donor
screen
infect
cytomegaloviru
herp
viru
tuberculosi
hepat
b
c
syphili
human
immunodefi
cienci
viru
pretranspl
infect
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococcu
vre
lead
posttranspl
infect
howev
colon
pathogen
contraind
transplant
addit
risk
factor
includ
surgic
complic
transplant
exampl
risk
bacteri
infect
increas
undergo
rouxeni
biliari
anastomosi
multipl
abdomin
surgeri
patient
develop
reject
poor
graft
function
also
increas
risk
infect
aggress
immunosuppress
requir
minim
infect
includ
strategi
appropri
vaccin
prior
transplant
particularli
sinc
antireject
immunosuppress
medic
prevent
develop
optim
respons
vaccin
certain
vaccin
pneumococc
infl
uenza
vaccin
may
need
repeat
transplant
live
vaccin
avoid
transplant
recipi
due
potenti
risk
dissemin
diseas
higher
chanc
develop
surgic
site
infect
liver
transplant
recipi
compar
solid
organ
transplant
treatment
trimethoprim
sulfamethoxazol
gener
use
liver
transplant
month
reduc
risk
pneumocysti
also
prevent
infect
listeria
nocardia
toxoplasma
mani
common
infect
dose
singlestrength
tablet
taken
daili
doublestrength
tablet
taken
thrice
week
common
advers
effect
allergi
myelosuppress
also
import
note
higher
dose
may
increas
nephrotox
associ
cyclosporin
tacrolimu
although
cytomegaloviru
remain
import
viral
infect
posttranspl
virus
hsv
vzv
signifi
cant
pathogen
ganciclovir
valganciclovir
use
posttranspl
viral
prophylaxi
cmvneg
transplant
recipi
receiv
organ
cmv
seroposit
donor
increas
risk
develop
cmv
reactiv
posttranspl
cmv
seroposit
recipi
lower
risk
cmv
donorrecipi
neg
patient
least
risk
cmv
activ
infect
cmv
viru
increas
risk
bacteri
fungal
infect
lead
almost
fourfold
increas
risk
death
year
posttranspl
fungal
infect
also
problemat
posttranspl
set
candida
albican
commonli
seen
fungal
pathogen
although
infect
nonalbican
candida
may
occur
role
antifung
treatment
prophylaxi
well
studi
howev
fl
uconazol
liposom
amphotericin
b
day
use
postop
antifung
prophylaxi
highrisk
liver
transplant
recipi
renal
failur
fulmin
hepat
failur
prolong
hospit
prolong
antibiot
use
larg
transfus
requir
patient
liver
transplant
remain
increas
risk
develop
activ
mycobacterium
tuberculosi
infect
although
optim
treat
latent
tb
prior
transplant
diffi
cult
signific
hepatotox
isoniazid
treatment
sometim
attempt
transplant
fi
rst
month
immedi
follow
transplant
bacteri
infect
predomin
usual
nosocomi
sourc
indwel
cathet
drain
prolong
intub
increas
risk
infect
abdomin
abscess
cholang
wound
infect
nosocomi
pneumonia
common
clostridium
diffi
cile
coliti
may
also
occur
fig
bacteri
infect
suspect
transplant
recipi
empir
broadspectrum
antibiot
use
sensit
identifi
ed
aminoglycosid
usual
avoid
due
nephrotox
particularli
calcineurin
inhibitor
use
immunosuppress
common
organ
isol
bacterem
patient
methicillinresist
staphylococcu
aureu
klebsiella
pneumonia
pseudomona
aeruginosa
beyond
immedi
posttranspl
period
infect
cytomegaloviru
vzv
epsteinbarr
viru
respiratori
syncyti
viru
human
herpesviru
infl
uenza
viru
adenoviru
may
occur
infect
ebv
import
potenti
induc
posttranspl
lymphoprolif
diseas
invas
aspergillosi
associ
high
mortal
opportunist
infect
becom
uncommon
beyond
fi
rst
month
transplant
howev
sinc
patient
immunocompromis
increas
risk
infect
pathogen
cryptococcu
neoforman
legionella
also
west
nile
viru
respiratori
infect
due
pathogen
streptococcu
pneumonia
haemophilu
infl
uenza
may
life
threaten
promptli
treat
recurr
infect
ebv
cmv
herpesviru
may
occur
may
devast
fungal
infect
histoplasma
coccidioid
blastomyc
may
seen
late
posttranspl
period
listeria
infect
may
manifest
hepat
bacteremia
mening
